Clinical efficacy of cabozantinib in two pediatric patients with
relapsed and refractory Ewing sarcoma
Ewing sarcoma is children’s second most common malignant bone tumor
after osteosarcoma. Relapsed and/or treatment-refractory cases have a
poor prognosis. Cabozantinib is a tyrosine kinase inhibitor (TKI) that
targets vascular endothelial growth factor (VEGF) and MET. Here, we
present data on two children with metastatic Ewing sarcoma who received
cabozantinib therapy. In both cases, the disease regressed
significantly, symptoms improved, and side effects were manageable.
Further research is needed to determine whether cabozantinib can
maintain sustained disease control in children with Ewing sarcoma.